Portfolio Update: Glycotest and ProAxsis

AI SummaryClose X

EMV Capital plc has announced significant developments for its portfolio companies, Glycotest and ProAxsis, which will result in their deconsolidation as EMV Capital no longer exercises control. Glycotest successfully closed a first tranche fundraising of approximately $3.22 million, with EMV Capital converting $0.97 million of its convertible loan and retaining a 48.67% equity holding valued at £13.7 million post-investment, a 24.3% increase. ProAxsis has completed a share capital reorganisation to qualify for EIS funding and is proposing a fundraising of up to £1 million, with EMV Capital's equity holding now at 49.87%. Additionally, ProAxsis has entered into a loan agreement with AB Group Limited for approximately £525,000, which includes warrants representing 3.08% of ProAxsis's fully diluted share capital.

Disclaimer*

Companies

Emv Capital (EMVC)
UK 100

Latest directors dealings